Temporal trends in peritonitis rates, microbiology and outcomes: the major clinical complication of peritoneal dialysis

Blood Purif. 2012;33(4):284-91. doi: 10.1159/000337377. Epub 2012 May 10.

Abstract

Peritonitis remains a common complication of peritoneal dialysis (PD). The aim of this study was to analyze, in a PD center, long-term temporal trends in peritonitis rates, microbiology and outcomes. We treated 588 cases of peritonitis that occurred during 11,833.6 months at risk. Y-set and twin-bag disconnecting systems were introduced in 1990, mupirocin at the exit site in 2000 and fluconazole prophylaxis in 2005. Vancomycin and ceftazidime were the empiric protocol. Global and 5-year cohort rates were expressed as episodes/patient-year (ep/p-y). A global peritonitis rate reduction was found from 1.02 to 0.47 ep/p-y (p = 0.008). Poisson analyses performed in each of the subgroups of Gram-positive and Gram-negative peritonitis revealed no significant changes over time. No case of vancomycin resistance was identified. There was a downward trend in peritonitis-related hospitalization over time to 0.11 ep/p-y (p ≤ 0.001). Trend analysis showed a favorable, but changing evolution, highlighting the importance of accurate longitudinal PD center registry data and quality control.

MeSH terms

  • Adult
  • Anti-Bacterial Agents / therapeutic use*
  • Antifungal Agents / therapeutic use
  • Bacteria / isolation & purification
  • Bacterial Infections / drug therapy
  • Bacterial Infections / etiology
  • Bacterial Infections / microbiology
  • Ceftazidime / therapeutic use*
  • Cohort Studies
  • Female
  • Fluconazole / therapeutic use
  • Humans
  • Kidney Failure, Chronic / therapy
  • Male
  • Middle Aged
  • Mupirocin / therapeutic use
  • Peritoneal Dialysis / adverse effects*
  • Peritonitis / drug therapy*
  • Peritonitis / etiology
  • Peritonitis / microbiology*
  • Treatment Outcome
  • Vancomycin / therapeutic use*

Substances

  • Anti-Bacterial Agents
  • Antifungal Agents
  • Vancomycin
  • Fluconazole
  • Ceftazidime
  • Mupirocin